CN105407873A - 包含降血脂剂的制剂 - Google Patents

包含降血脂剂的制剂 Download PDF

Info

Publication number
CN105407873A
CN105407873A CN201480041453.7A CN201480041453A CN105407873A CN 105407873 A CN105407873 A CN 105407873A CN 201480041453 A CN201480041453 A CN 201480041453A CN 105407873 A CN105407873 A CN 105407873A
Authority
CN
China
Prior art keywords
pharmaceutical composition
sodium
composition according
agent
starch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480041453.7A
Other languages
English (en)
Chinese (zh)
Inventor
吉唐德尔·D·帕特尔
普拉卡什·达瓦德拉
斯内哈·帕特尔
沙菲克·谢赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of CN105407873A publication Critical patent/CN105407873A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480041453.7A 2013-07-25 2014-07-24 包含降血脂剂的制剂 Pending CN105407873A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2470MU2013 IN2013MU02470A (2) 2013-07-25 2013-07-25
IN2470/MUM/2013 2013-07-25
PCT/IN2014/000489 WO2015011730A1 (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent

Publications (1)

Publication Number Publication Date
CN105407873A true CN105407873A (zh) 2016-03-16

Family

ID=51787141

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480041453.7A Pending CN105407873A (zh) 2013-07-25 2014-07-24 包含降血脂剂的制剂

Country Status (22)

Country Link
US (2) US9610277B2 (2)
EP (1) EP3024446A1 (2)
JP (1) JP2016523895A (2)
KR (1) KR101786843B1 (2)
CN (1) CN105407873A (2)
AP (1) AP2015008876A0 (2)
AR (1) AR097067A1 (2)
AU (1) AU2014294548B2 (2)
BR (1) BR112015031878A2 (2)
CA (1) CA2917923A1 (2)
EA (1) EA201690072A1 (2)
GE (1) GEP20186825B (2)
HK (1) HK1219222A1 (2)
IN (1) IN2013MU02470A (2)
MA (1) MA38865A1 (2)
MX (1) MX374628B (2)
NZ (1) NZ714558A (2)
PH (1) PH12015502802A1 (2)
SG (1) SG11201509798PA (2)
TW (1) TW201545773A (2)
WO (1) WO2015011730A1 (2)
ZA (1) ZA201508682B (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006020785D1 (de) 2006-05-23 2011-04-28 Intel Corp Millimeterwellen-kommunikationssystem für den innenraum
EP3009136A1 (en) 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
IN2013MU01468A (2) 2013-04-22 2015-04-17 Cadila Healthcare Ltd
PH12015502667B1 (en) 2013-05-30 2023-10-18 Zydus Lifesciences Ltd A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (2) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (2) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR101913830B1 (ko) * 2016-12-05 2018-10-31 주식회사 코쿤디자인 기능성 led 어셈블리를 이용한 디스플레이 장치
BR112019011740A2 (pt) 2016-12-09 2019-10-29 Cadila Healthcare Limited composição farmacêutica e método para o tratamento de colangite biliar primária
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
US20220169603A1 (en) * 2019-03-11 2022-06-02 Cadila Healthcare Ltd. Novel salts, crystalline forms and premix of hypolipidemic agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1036508A (zh) * 1988-03-31 1989-10-25 E·R·斯奎布父子公司 具有良好稳定性的药物制剂
US20120121729A1 (en) * 2010-10-12 2012-05-17 Blake Paterson Antitussive compositions comprising memantine
WO2012104869A1 (en) * 2011-01-31 2012-08-09 Cadila Healthcare Limited Treatment for lipodystrophy
CN105377246A (zh) * 2013-04-22 2016-03-02 卡迪拉保健有限公司 针对非酒精性脂肪性肝病(nafld)的新组合物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
CA2139442A1 (en) 1992-07-03 1994-01-20 David Haigh Heterocyclic compounds as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
EP0826688B1 (en) 1995-04-28 2001-09-05 Daiichi Pharmaceutical Co., Ltd. Pentacyclic compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
ATE286032T1 (de) 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
JP2002507543A (ja) 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
ES2449194T3 (es) 2000-01-19 2014-03-18 Cadila Healthcare Limited Compuestos que tienen actividades hipolipidémica e hipocolesterolémica, procedimiento para su preparación y composiciones farmacéuticas que los contienen
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001286163A1 (en) 2000-09-22 2002-04-02 Dr. Reddy's Research Foundation An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4745616B2 (ja) * 2003-02-26 2011-08-10 武田薬品工業株式会社 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
US20070051626A1 (en) 2003-09-26 2007-03-08 Chiho Itou Cataphoresis apparatus cataphoresis method, and detection method for organism-related material using the apparatus and the method
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
CN101389333A (zh) * 2006-02-22 2009-03-18 卫材R&D管理有限公司 稳定化药物组合物
EP2018157A2 (en) 2006-04-26 2009-01-28 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
EA020849B1 (ru) 2009-11-26 2015-02-27 Женфит Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
PH12015502667B1 (en) 2013-05-30 2023-10-18 Zydus Lifesciences Ltd A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (2) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (2) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1036508A (zh) * 1988-03-31 1989-10-25 E·R·斯奎布父子公司 具有良好稳定性的药物制剂
US20120121729A1 (en) * 2010-10-12 2012-05-17 Blake Paterson Antitussive compositions comprising memantine
WO2012104869A1 (en) * 2011-01-31 2012-08-09 Cadila Healthcare Limited Treatment for lipodystrophy
CN105377246A (zh) * 2013-04-22 2016-03-02 卡迪拉保健有限公司 针对非酒精性脂肪性肝病(nafld)的新组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
慕慧 主编: "《基础化学实验》", 28 February 2013 *
梅兴国 主编: "《生物技术药物制剂-基础与应用》", 31 October 2004 *

Also Published As

Publication number Publication date
US9610277B2 (en) 2017-04-04
HK1219222A1 (zh) 2017-03-31
AP2015008876A0 (en) 2015-11-30
WO2015011730A1 (en) 2015-01-29
EP3024446A1 (en) 2016-06-01
PH12015502802A1 (en) 2016-03-14
AR097067A1 (es) 2016-02-17
IN2013MU02470A (2) 2015-06-26
CA2917923A1 (en) 2015-01-29
BR112015031878A2 (pt) 2017-07-25
MX2015016971A (es) 2016-04-25
KR101786843B1 (ko) 2017-10-18
US10098868B2 (en) 2018-10-16
TW201545773A (zh) 2015-12-16
ZA201508682B (en) 2017-03-29
AU2014294548A1 (en) 2015-12-17
EA201690072A1 (ru) 2016-06-30
MA38865A1 (fr) 2017-12-29
AU2014294548B2 (en) 2017-08-10
SG11201509798PA (en) 2016-02-26
MX374628B (es) 2025-03-06
US20160136131A1 (en) 2016-05-19
US20170266158A1 (en) 2017-09-21
GEP20186825B (en) 2018-02-26
JP2016523895A (ja) 2016-08-12
NZ714558A (en) 2017-02-24
KR20160013150A (ko) 2016-02-03

Similar Documents

Publication Publication Date Title
CN105407873A (zh) 包含降血脂剂的制剂
CN101686976B (zh) 含有4,5-环氧基吗啡喃衍生物的稳定的固体制剂
JP2006514052A (ja) 吸湿性および／または潮解性の薬剤を含む固体分散剤
CN101951889A (zh) 伊马替尼组合物
US8779000B1 (en) Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production
CN107530342A (zh) 口服给药用医药组合物
JP5465867B2 (ja) 安定なエグアレンナトリウム固形製剤
US20180325852A1 (en) Alditol-free, storage-stable thyroid hormone active drug formulations and methods for their production
JP7355846B2 (ja) 固形製剤
US9775832B2 (en) Pharmaceutical composition for oral administration
JP2020183382A (ja) フィンゴリモド塩酸塩含有製剤及びフィンゴリモド塩酸塩含有製剤の製造方法
CN103126994B (zh) 含决奈达隆的固体药物组合物
JP7608444B2 (ja) インドールアミン２，３－ジオキシゲナーゼ阻害剤の医薬製剤
US20250248977A1 (en) Tablet Formulation Of Tafamidis Or Pharmaceutically Acceptable Salt Thereof
WO2025166343A1 (en) Tablet formulation of tafamidis or pharmaceutically acceptable salt thereof
JP5878510B2 (ja) 安定なエグアレンナトリウム固形製剤
KR20250122522A (ko) (R)-1-(1-아크릴로일피페리딘-3-일)-4-아미노-3-(4-페녹시페닐)-1H-이미다조[4,5-c]피리딘-2(3H)-온의약물 제형
EA045037B1 (ru) Фармацевтические составы ингибиторов индоламин-2,3-диоксигеназы
OA17603A (en) Formulation comprising a hypolipidemic agent.
WO2018216933A1 (ko) 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
US20150133557A1 (en) Alditol free and saccharide free storage-stable thyroid hormone active drug formulations and methods for their production

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160316

WD01 Invention patent application deemed withdrawn after publication